Cargando…
Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma
The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute to the deficiency of tumor-infiltrating T cells. However, the current studies focus heavily on the local immunosuppre...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880004/ https://www.ncbi.nlm.nih.gov/pubmed/36702831 http://dx.doi.org/10.1038/s41467-023-35957-8 |
_version_ | 1784878816726876160 |
---|---|
author | Zhou, Songlei Huang, Yukun Chen, Yu Liu, Yipu Xie, Laozhi You, Yang Tong, Shiqiang Xu, Jianpei Jiang, Gan Song, Qingxiang Mei, Ni Ma, Fenfen Gao, Xiaoling Chen, Hongzhuan Chen, Jun |
author_facet | Zhou, Songlei Huang, Yukun Chen, Yu Liu, Yipu Xie, Laozhi You, Yang Tong, Shiqiang Xu, Jianpei Jiang, Gan Song, Qingxiang Mei, Ni Ma, Fenfen Gao, Xiaoling Chen, Hongzhuan Chen, Jun |
author_sort | Zhou, Songlei |
collection | PubMed |
description | The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute to the deficiency of tumor-infiltrating T cells. However, the current studies focus heavily on the local immunosuppressive tumor microenvironment but not on the co-existence of systemic immunosuppression. Here, we develop a nanostructure named Nano-reshaper to co-encapsulate lymphopenia alleviating agent cannabidiol and lymphocyte recruiting cytokine LIGHT. The results show that Nano-reshaper increases the number of systemic T cells and improves local T-cell recruitment condition, thus greatly increasing T-cell infiltration. When combined with immune checkpoint inhibitor, this therapeutic modality achieves 83.3% long-term survivors without recurrence in GBM models in male mice. Collectively, this work unveils that simultaneous reprogramming of systemic and local immune function is critical for T-cell based immunotherapy and provides a clinically translatable option for combating brain tumors. |
format | Online Article Text |
id | pubmed-9880004 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-98800042023-01-28 Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma Zhou, Songlei Huang, Yukun Chen, Yu Liu, Yipu Xie, Laozhi You, Yang Tong, Shiqiang Xu, Jianpei Jiang, Gan Song, Qingxiang Mei, Ni Ma, Fenfen Gao, Xiaoling Chen, Hongzhuan Chen, Jun Nat Commun Article The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute to the deficiency of tumor-infiltrating T cells. However, the current studies focus heavily on the local immunosuppressive tumor microenvironment but not on the co-existence of systemic immunosuppression. Here, we develop a nanostructure named Nano-reshaper to co-encapsulate lymphopenia alleviating agent cannabidiol and lymphocyte recruiting cytokine LIGHT. The results show that Nano-reshaper increases the number of systemic T cells and improves local T-cell recruitment condition, thus greatly increasing T-cell infiltration. When combined with immune checkpoint inhibitor, this therapeutic modality achieves 83.3% long-term survivors without recurrence in GBM models in male mice. Collectively, this work unveils that simultaneous reprogramming of systemic and local immune function is critical for T-cell based immunotherapy and provides a clinically translatable option for combating brain tumors. Nature Publishing Group UK 2023-01-26 /pmc/articles/PMC9880004/ /pubmed/36702831 http://dx.doi.org/10.1038/s41467-023-35957-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhou, Songlei Huang, Yukun Chen, Yu Liu, Yipu Xie, Laozhi You, Yang Tong, Shiqiang Xu, Jianpei Jiang, Gan Song, Qingxiang Mei, Ni Ma, Fenfen Gao, Xiaoling Chen, Hongzhuan Chen, Jun Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma |
title | Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma |
title_full | Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma |
title_fullStr | Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma |
title_full_unstemmed | Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma |
title_short | Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma |
title_sort | reprogramming systemic and local immune function to empower immunotherapy against glioblastoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9880004/ https://www.ncbi.nlm.nih.gov/pubmed/36702831 http://dx.doi.org/10.1038/s41467-023-35957-8 |
work_keys_str_mv | AT zhousonglei reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT huangyukun reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT chenyu reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT liuyipu reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT xielaozhi reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT youyang reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT tongshiqiang reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT xujianpei reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT jianggan reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT songqingxiang reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT meini reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT mafenfen reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT gaoxiaoling reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT chenhongzhuan reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma AT chenjun reprogrammingsystemicandlocalimmunefunctiontoempowerimmunotherapyagainstglioblastoma |